Evidence map›Paper›PMID 41282862›Full record

ArticlemedRxiv : the preprint server for health sciences2025

CD8

David R Collins, Mpho J Olatotse, Jonathan M Urbach, Zhu Zhuo, Suhui Zhao, Tyler J Lilie, Rachel Raymond, Xianbao He, James Y Chen, Bridget Coffey and 16 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

David R CollinsRagon Institute of Mass General Brigham, MIT and Harvard; Cambridge, MA, USA.
Mpho J OlatotseRagon Institute of Mass General Brigham, MIT and Harvard; Cambridge, MA, USA.
Jonathan M UrbachRagon Institute of Mass General Brigham, MIT and Harvard; Cambridge, MA, USA.
Zhu ZhuoHarvard Chan Bioinformatics Core, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Suhui ZhaoDivision of Infectious Diseases, Brigham and Women's Hospital; Boston, MA, USA.
Tyler J LilieDivision of Infectious Diseases, Brigham and Women's Hospital; Boston, MA, USA.
Rachel RaymondDivision of Infectious Diseases, Brigham and Women's Hospital; Boston, MA, USA.
Xianbao HeDepartment of Medicine, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine; Boston, MA, USA.
James Y ChenRagon Institute of Mass General Brigham, MIT and Harvard; Cambridge, MA, USA.
Bridget CoffeyRagon Institute of Mass General Brigham, MIT and Harvard; Cambridge, MA, USA.
Umar ArshadRagon Institute of Mass General Brigham, MIT and Harvard; Cambridge, MA, USA.
Zachary J RacenetRagon Institute of Mass General Brigham, MIT and Harvard; Cambridge, MA, USA.
Hannah WisnerRagon Institute of Mass General Brigham, MIT and Harvard; Cambridge, MA, USA.
Carlos CasqueroRagon Institute of Mass General Brigham, MIT and Harvard; Cambridge, MA, USA.
Xuan GuoRagon Institute of Mass General Brigham, MIT and Harvard; Cambridge, MA, USA.
Lucy C WaltersRagon Institute of Mass General Brigham, MIT and Harvard; Cambridge, MA, USA.
Jennifer M DavisDivision of Infectious Diseases, University of Nebraska Medical Center; Omaha, NE, USA.
Hannah C JordanDivision of Infectious Diseases, Brigham and Women's Hospital; Boston, MA, USA.
Noor SohailHarvard Chan Bioinformatics Core, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Kiera L ClaytonDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID 0009-0006-9398-0651
Manish SagarDepartment of Medicine, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine; Boston, MA, USA.ORCID 0000-0001-9803-6594
James BillingsleyHarvard Chan Bioinformatics Core, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Shannan Ho SuiHarvard Chan Bioinformatics Core, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Emanuele MazzolaDepartment of Data Science, Dana-Farber Cancer Institute; Boston, MA, USA.ORCID 0000-0003-0561-7336
Bruce D WalkerRagon Institute of Mass General Brigham, MIT and Harvard; Cambridge, MA, USA.ORCID 0000-0001-6122-9245
Athe TsibrisDivision of Infectious Diseases, Brigham and Women's Hospital; Boston, MA, USA.ORCID 0000-0002-2681-3216

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
The Harvard Clinical and Translational Science CenterUL1TR002541 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2018 to 2022
$93.0M
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH, DEBBIE M. CHENG · 1998 to 2026
$51.7M
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 3P01AI169768 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Athe M. Tsibris · 2022 to 2026
$10.1M
Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8M
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapyR01AI157854 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI KURITZKES, DANIEL R., TSIBRIS, ATHE M. · 2021 to 2025
$4.0M
Antibody dependent cellular cytotoxicity and HIV-1 mother to child transmissionR01AI172843 · NIAID · BOSTON MEDICAL CENTER · PI SAGAR, MANISH · 2022 to 2025
$3.5M
Understanding and Reversing T Cell Dysfunction to Control and Eliminate Persistent HIV ReservoirsR01AI149704 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 2020 to 2024
$2.1M
Modulating T Cell Activation to Combat HIV PersistenceDP2AI184606 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI David Randolph Collins · 2024 to 2026
$1.5M
NCATS NIH HHS UL1 TR002541NIAID NIH HHS DP2 AI184606NIAID NIH HHS L30 AI126472NIAID NIH HHS P01 AI169768NIAID NIH HHS P30 AI042853NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI149704NIAID NIH HHS R01 AI157854NIAID NIH HHS R01 AI172843NIAID NIH HHS T32 AI007387
6 · The paper itself

Abstract

The combination of replication-competent HIV-1 proviral persistence and virus-specific immune dysfunction prevents virus clearance during antiretroviral therapy (ART), resulting in rebound viremia after treatment interruption. Functional impairment of HIV-specific CD8

Identifiers

PMID41282862
PMCPMC12633139

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.